Toll-like receptor agonists: Current status and future perspective on their utility as adjuvants in improving antic ancer vaccination strategies

Immunotherapy

Volumn 5, Issue 5, 2013, Pages 497-511

  Baxevanis, Constantin N ^a   Voutsas, Ioannis F ^a   Tsitsilonis, Ourania E ^b  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

adjuvant; anticancer vaccination; DAMP; prothymosin ; Toll like receptor; Toll like receptor agonist

Indexed keywords

AGATOLIMOD; AS 02B; AS 15; BIOSTIM; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; HEPATITIS B VACCINE; IMIQUIMOD; LAPATINIB; MELANOMA ANTIGEN 3; PHOSPHORYL LIPID A; PICIBANIL; PROTHYMOSIN ALPHA; RESIQUIMOD; TOLL LIKE RECEPTOR AGONIST; TRASTUZUMAB; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); DROSOPHILA; DRUG FORMULATION; DRUG MECHANISM; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROTEIN PRECURSORS; RATS; THYMOSIN; TOLL-LIKE RECEPTORS; TREATMENT OUTCOME;

EID: 84877284039     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.24     Document Type: Review

References (125)

1. Vacchelli E, Galluzzi L, Eggermont A et al. Trial watch: FDA-approved Tolllike receptor agonists for cancer therapy. Oncoimmunology 1(6), 894-907 (2012).
2. Anderson KV, Bokla L, Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 42(3), 791-798 (1985).
3. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388(6640), 394-397 (1997).
4. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy 1(6), 949-964 (2009).
5. Kawai T, Akira S. TLR signaling. Semin. Immunol. 19(1), 24-32 (2007).
6. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8(4), 279-289 (2008).
7. Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol. 7(1), 29-54 (2012).
8. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat. Rev. Immunol. 9(8), 535-542 (2009).
9. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc. Natl Acad. Sci. USA 101(9), 3029-3034 (2004).
10. Bell MP, Svingen PA, Rahman MK, Xiong Y, Faubion WA Jr. FOXP3 regulates TLR10 expression in human T regulatory cells. J. Immunol. 179(3), 1893-1900 (2007).
11. Schreibelt G, Tel J, Sliepen KH et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol. Immunother. 59(10), 1573-1582 (2010).
12. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13(5), 552-559 (2007).
13. Gribar SC, Anand RJ, Sodhi CP, Hackam DJ. The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation. J. Leukoc. Biol. 83(3), 493-498 (2008).
14. Grote K, Schutt H, Schieffer B. Toll-like receptors in angiogenesis. ScientificWorldJournal 11, 981-991 (2011).
15. Kollisch G, Kalali BN, Voelcker V et al. Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 114(4), 531-541 (2005).
16. Hasan UA, Trinchieri G, Vlach J. Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts. J. Biol. Chem. 280(21), 20620-20627 (2005).
17. Hwa Cho H, Bae YC, Jung JS. Role of Toll-like receptors on human adipose-derived stromal cells. Stem Cells 24(12), 2744-2752 (2006).
18. Bsibsi M, Ravid R, Gveric D, Van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J. Neuropathol. Exp. Neurol. 61(11), 1013-1021 (2002).
19. Chin AI, Miyahira AK, Covarrubias A et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res. 70(7), 2595-2603 (2010).
20. Wang D, Precopio M, Lan T et al. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8. Mol. Cancer Ther. 9(6), 1788-1797 (2010).
21. Nierkens S, Den Brok MH, Garcia Z et al. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res. 71(20), 6428-6437 (2011).
22. Hartmann E, Wollenberg B, Rothenfusser S et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 63(19), 6478-6487 (2003).
23. Huang B, Zhao J, Li H et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65(12), 5009-5014 (2005).
24. Huang B, Zhao J, Shen S et al. Listeria monocytogenes promotes tumor growth via tumor cell Toll-like receptor 2 signaling. Cancer Res. 67(9), 4346-4352 (2007).
25. Berger R, Fiegl H, Goebel G et al. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. 101(4), 1059-1066 (2010).
26. Hasan UA, Bates E, Takeshita F et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 178(5), 3186-3197 (2007).
27. Ilvesaro JM, Merrell MA, Swain TM et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 67(7), 774-781 (2007).
28. Merrell MA, Ilvesaro JM, Lehtonen N et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol. Cancer Res. 4(7), 437-447 (2006).
29. Brignole C, Marimpietri D, Di Paolo D et al. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Cancer Res. 70(23), 9816-9826 (2010).
30. Whitson JM, Noonan EJ, Pookot D, Place RF, Dahiya R. Double stranded-RNA-mediated activation of P21 gene induced apoptosis and cell cycle arrest in renal cell carcinoma. Int. J. Cancer 125(2), 446-452 (2009).
31. Paone A, Starace D, Galli R et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 29(7), 1334-1342 (2008).
32. Jiang Q, Wei H, Tian Z. Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR-3 pathway. BMC Cancer 8, 12 (2008).
33. Taura M, Fukuda R, Suico MA et al. TLR-3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis. Cancer Sci. 101(7), 1610-1617 (2010).
34. Salaun B, Zitvogel L, Asselin-Paturel C et al. TLR-3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res. 71(5), 1607-1614 (2011).
35. Weber A, Kirejczyk Z, Besch R, Potthoff S, Leverkus M, Hacker G. Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ. 17(6), 942-951 (2010).
36. Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 71(7), 2466-2475 (2011).
37. Kelly MG, Alvero AB, Chen R et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 66(7), 3859-3868 (2006).
38. Szczepanski MJ, Czystowska M, Szajnik M et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 69(7), 3105-3113 (2009).
39. Busch W. [Negotiations medical companies]. Berl. Klin. Wochenschr. 5, 137-138 (1868).
40. Coley W. The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases. Am. J. Med. Sci. 105, 487-511 (1893).
41. Bickels J, Kollender Y, Merinsky O, Meller I. Coley's toxin: historical perspective. Isr. Med. Assoc. J. 4(6), 471-472 (2002).
42. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol. Rev. 222, 357-368 (2008).
43. Lamm DL, Crissmann J, Blumenstein B et al. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study. Prog. Clin. Biol. Res. 310, 263-270 (1989).
44. Lockyer CR, Gillatt DA. BCG immunotherapy for superficial bladder cancer. J. R. Soc. Med. 94(3), 119-123 (2001).
45. Vermorken JB, Claessen AM, Van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353(9150), 345-350 (1999).
46. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus Phase I and GM-CSF. J. Immunother. 31(9), 849-857 (2008).
47. Thompson BS, Chilton PM, Ward JR, Evans JT, Mitchell TC. The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J. Leukoc. Biol. 78(6), 1273-1280 (2005).
48. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv. Exp. Med. Biol. 667, 111-123 (2010).
49. Vansteenkiste J, Zielinski M, Linder A et al. Final results of a multicenter, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in Stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25(Suppl. 18), Abstract 7554 (2007).
50. Hamilton E, Blackwell K, Hobeika AC et al. Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion. J. Transl. Med. 10, 28 (2012).
51. Kruit W, Suciu S, Dreno B et al. Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: four-year follow-up results from a randomized Phase II study (EORTC 16032-18031). J. Clin. Oncol. 29(Suppl.), Abstract 8535 (2011).
52. Therasse P, Vansteenkiste JF, Zielinski M et al. MAGRIT Phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with competely resected stage IB-IIIA NSCLC. J. Clin. Oncol. 29(Suppl. 15), Abstract TPS210 (2011).
53. Thompson JF, Santinami M, Jouary T et al. MAGE-A3 expression in patients screened for the DERMA trial: a Phase III trial testing MAGE-A3 immunotherapeutic in the adjuvant setting for stage IIIB-C-Tx melanoma. J. Clin. Oncol. 30(Suppl.), Abstract 8559 (2012).
54. Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared with aluminium salt only. Vaccine 24(33-34), 5937-5949 (2006).
55. Eton O, Kharkevitch DD, Gianan MA et al. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. Clin. Cancer Res. 4(3), 619-627 (1998).
56. Badie B, Berlin JM. The future of CpG immunotherapy in cancer. Immunotherapy 5(1), 1-3 (2013).
57. Gendron KB, Rodriguez A, Sewell DA. Vaccination with human papillomavirus type 16 E7 peptide with CpG oligonucleotides for prevention of tumor growth in mice. Arch. Otolaryngol. Head Neck Surg. 132(3), 327-332 (2006).
58. Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115(3), 739-746 (2005).
59. Valmori D, Souleimanian NE, Tosello V et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl Acad. Sci. USA 104(21), 8947-8952 (2007).
60. Karbach J, Gnjatic S, Bender A et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and montanide ISA-51: association with survival. Int. J. Cancer 126(4), 909-918 (2010).
61. Haining WN, Davies J, Kanzler H et al. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin. Cancer Res. 14(17), 5626-5634 (2008).
62. Brody JD, Ai WZ, Czerwinski DK et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a Phase I/II study. J. Clin. Oncol. 28(28), 4324-4332 (2010).
63. Ohno S, Okuyama R, Aruga A, Sugiyama H, Yamamoto M. Phase I trial of Wilms' tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy. Anticancer Res. 32(6), 2263-2269 (2012).
64. Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/ TLR-3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J. Immunother. 28(3), 220-228 (2005).
65. Wieckowski E, Chatta GS, Mailliard RM et al. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes. Prostate 71(2), 125-133 (2011).
66. Navabi H, Jasani B, Reece A et al. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27(1), 107-115 (2009).
67. Nair S, McLaughlin C, Weizer A et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171(11), 6275-6282 (2003).
68. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J. Immunol. 173(5), 3051-3061 (2004).
69. Shackleton M, Davis ID, Hopkins W et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 4, 9 (2004).
70. Adams S, O'Neill DW, Nonaka D et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181(1), 776-784 (2008).
71. Feyerabend S, Stevanovic S, Gouttefangeas C et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 69(9), 917-927 (2009).
72. Trakatelli M, Toungouz M, Blocklet D et al. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol. Immunother. 55(4), 469-474 (2006).
73. Czerniecki BJ, Koski GK, Koldovsky U et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 67(4), 1842-1852 (2007).
74. Wilgenhof S, Van Nuffel AM, Corthals J et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J. Immunother. 34(5), 448-456 (2011).
75. Galluzzi L, Vacchelli E, Eggermont A et al. Trial watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 1(5), 699-716 (2012).
76. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10(12), 826-837 (2010).
77. Fucikova J, Kralikova P, Fialova A et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res. 71(14), 4821-4833 (2011).
78. Haritos AA, Goodall GJ, Horecker BL. Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. Proc. Natl Acad. Sci. USA 81(4), 1008-1011 (1984).
79. Hannappel E, Huff T. The thymosins. Prothymosin alpha, parathymosin, and beta-thymosins: structure and function. Vitam. Horm. 66, 257-296 (2003).
80. Ioannou K, Samara P, Livaniou E, Derhovanessian E, Tsitsilonis OE. Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy. Cancer Immunol. Immunother. 61(5), 599-614 (2012).
81. Baxevanis CN, Gritzapis AD, Dedoussis GV, Papadopoulos NG, Tsolas O, Papamichail M. Induction of lymphokine-activated killer activity in mice by prothymosin alpha. Cancer Immunol. Immunother. 38(4), 281-286 (1994).
82. Baxevanis CN, Gritzapis AD, Spanakos G, Tsitsilonis OE, Papamichail M. Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha. Cancer Immunol. Immunother. 40(6), 410-418 (1995).
83. Baxevanis CN, Reclos GJ, Papamichail M. Prothymosin alpha restores depressed allogeneic cell-mediated lympholysis and natural-killer-cell activity in patients with cancer. Int. J. Cancer 53(2), 264-268 (1993).
84. Eckert K, Grunberg E, Garbin F, Maurer HR. Preclinical studies with prothymosin alpha1 on mononuclear cells from tumor patients. Int. J. Immunopharmacol. 19(9-10), 493-500 (1997).
85. Baxevanis CN, Spanakos G, Voutsas IF et al. Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha. Cancer Immunol. Immunother. 48(2-3), 71-84 (1999).
86. Cordero OJ, Sarandeses C, Lopez-Rodriguez JL, Nogueira M. The presence and cytotoxicity of CD16+ CD2-subset from PBL and NK cells in long-term IL-2 cultures enhanced by prothymosin-alpha. Immunopharmacology 29(3), 215-223 (1995).
87. Voutsas IF, Baxevanis CN, Gritzapis AD et al. Synergy between interleukin-2 and prothymosin alpha for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas. Cancer Immunol. Immunother. 49(8), 449-458 (2000).
88. Skopeliti M, Kratzer U, Altenberend F et al. Proteomic exploitation on prothymosin alpha-induced mononuclear cell activation. Proteomics 7(11), 1814-1824 (2007).
89. Mosoian A, Teixeira A, Burns CS et al. Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. Proc. Natl Acad. Sci. USA 107(22), 10178-10183 (2010).
90. Samara P, Ioannou K, Neagu M et al. The C-terminal decapeptide of prothymosin alpha is responsible for its stimulatory effect on the functions of human neutrophils in vitro. Int. Immunopharmacol. 15(1), 50-57 (2012).
91. Skopeliti M, Iconomidou VA, Derhovanessian E et al. Prothymosin alpha immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a beta-sheet conformation in a sequence-specific manner. Mol. Immunol. 46(5), 784-792 (2009).
92. Ioannou K, Derhovanessian E, Samara P et al. Prothymosin alpha and its carboxy-terminal decapeptide proTalpha(100-109) induce Th1-type tumor-specific immune responses. Presented at: 22nd Biennial Congress of the European Association for Cancer Research. Barcelona, Spain, 7-10 July 2012.
93. Voutsas IF, Pistamaltzian N, Tsiatas ML et al. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin alpha or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice. Eur. J. Cancer pii: S0959-8049(12)00956-2 (2012).
94. Evstafieva AG, Belov GA, Rubtsov YP et al. Apoptosis-related fragmentation, translocation, and properties of human prothymosin alpha. Exp. Cell. Res. 284(2), 211-223 (2003).
95. Aguilera R, Saffie C, Tittarelli A et al. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin. Cancer Res. 17(8), 2474-2483 (2011).
96. Ellerman JE, Brown CK, De Vera M et al. Masquerader: high mobility group box-1 and cancer. Clin. Cancer Res. 13(10), 2836-2848 (2007).
97. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8(1), 59-73 (2008).
98. Baxevanis CN. Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm. Expert Rev. Vaccines 11(3), 275-277 (2012).
99. Gulley JL, Madan RA, Schlom J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr. Oncol. 18(3), e150-e157 (2011).
100. Samulowitz U, Weber M, Weeratna R et al. A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. Oligonucleotides 20(2), 93-101 (2010).
101. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6(8), 769-776 (2005).
102. Bogunovic D, Manches O, Godefroy E et al. TLR4 engagement during TLR-3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res. 71(16), 5467-5476 (2011).
103. Dang Y, Wagner WM, Gad E et al. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin. Cancer Res. 18(11), 3122-3131 (2012).
104. Clinical trials database. www.clinicaltrials.gov
105. Evaluation of a new vaccine treatment for patients with metastatic skin cancer. http://clinicaltrials.gov/show/NCT01149343
106. GSK1572932A antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with non-small cell lung cancer. http://clinicaltrials.gov/show/ NCT00480025
107. A Phase III study to test the benefit of a new kind of anti-cancer treatment in patients with melanoma, after surgical removal of their tumor. http://clinicaltrials.gov/show/NCT00796445
108. Vaccine therapy with or without imiquimod in treating patients with grade 3 cervical intraepithelial neoplasia. http://clinicaltrials.gov/show/ NCT00788164
109. Therapeutic vaccination for patients with HPV16+ cervical intraepithelial neoplasia (CIN2/3). http://clinicaltrials.gov/show/NCT00988559
110. Safety study of HPV DNA vaccine to treat head and neck cancer patients. http://clinicaltrials.gov/show/NCT01493154
111. Agatolimod and trastuzumab in treating patients with locally advanced or metastatic breast cancer. http://clinicaltrials.gov/show/NCT00824733
112. Vaccine therapy in treating patients with previously treated stage II or stage III breast cancer. http://clinicaltrials.gov/show/NCT00640861
113. PSMA and TARP peptide vaccine with poly IC-LC adjuvant in HLA-A2 (+) patients with elevated PSA after initial definitive treatment. http://clinicaltrials.gov/show/NCT00694551
114. MUC1 vaccine in conjunction with poly-ICLC in patients with recurrent and/or advanced prostate cancer. http://clinicaltrials.gov/show/NCT00374049
115. Phase I oncovir poly IC:LC and NY-ESO-1/ gp100. http://clinicaltrials. gov/show/NCT01008527
116. Safety study of adjuvant vaccine to treat melanoma patients. http://clinicaltrials.gov/show/NCT01079741
117. MUC1 vaccine for triple-negative breast cancer. http://clinicaltrials. gov/show/ NCT00986609
118. Phase II study to assess the safety and immunogenicity of recMAGE-A3+AS15 ASCI with or without poly IC:LC. http://clinicaltrials.gov/show/NCT01437605
119. Study of the immune response of MUC1 (Mucin1) peptide vaccine for non-small cell lung cancer. http://clinicaltrials.gov/show/NCT01720836
120. A clinical trial of autologous oxidized tumor cell lysate vaccine for recurrent ovarian, fallopian tube or primary peritoneal cancer. http://clinicaltrials.gov/show/NCT01312389
121. Vaccine therapy in combination with rintatolimod and/or sargramostim in patients with stage II-IV HER2-positive breast cancer. http://clinicaltrials. gov/show/NCT01355393
122. Chemokine-modulatory regimen for recurrent resectable colorectal cancer. http://clinicaltrials.gov/show/NCT01545141
123. Peptide-based glioma vaccine IMA950 in patients with glioblastoma. http://clinicaltrials.gov/show/NCT01403285
124. Imiquimod for breast cancer patients with chest wall recurrence or skin metastases. http://clinicaltrials.gov/show/ NCT00899574
125. Dendritic cell vaccine for patients with brain tumors. http://clinicaltrials.gov/show/ NCT01204684